PUBLISHER: Grand View Research | PRODUCT CODE: 1552919
PUBLISHER: Grand View Research | PRODUCT CODE: 1552919
The global hospital acquired infection control market size is anticipated to reach USD 9.03 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 5.2% from 2024 to 2030. The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives, and the COVID-19 pandemic. The COVID-19 pandemic has emerged as a major catalyst for the market as it led to increased awareness and concern over HAIs. The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.
Governments and regulatory bodies prescribed several policies and guidelines to prevent cross-contamination and safeguard public health. To prevent nosocomial infections in healthcare facilities, infection control standards were implemented such as triage strategy and provision and proper distribution of equipment, in addition to standard precautions such as hand washing and use of personal protective equipment. In particular, the pandemic resulted in a surge in demand for consumables such as PPE, masks, and disinfectants.
The CDC, of the U.S. Department of Health and Human Services, provides an extensive library of guidelines on basic infection prevention and control, antibiotic resistance, device-associated infections, procedure-associated infections, and disease / organism-specific to promote the control of HAIs. In the wake of the pandemic, the CDC added COVID-19 infection control guidelines to its digital library.
Growing initiatives by market players also contribute to the growth of the market. These initiatives include strategic partnerships, mergers and acquisitions, and product development. In February 2021, for instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company's infection control business unit. In December 2020, Xenex launched LightStrike 6 as part of its patented lineup of pathogen-eliminating robots. The robots produce high-intensity broad-spectrum UV light and can also deactivate the COVID-19 virus in 2 minutes.